行情

EYEG

EYEG

Eyegate制药
NASDAQ

实时行情|Nasdaq Last Sale

6.80
-0.10
-1.45%
交易中 11:48 12/13 EST
开盘
6.89
昨收
6.90
最高
6.96
最低
6.75
成交量
1.11万
成交额
--
52周最高
9.50
52周最低
2.250
市值
2,472.79万
市盈率(TTM)
-2.7731
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EYEG 新闻

  • 早盘:美股涨幅收窄 道指短线跌逾100点
  • 新浪美股.1小时前
  • 平安集团旗下子公司金融壹账通上市首日开盘涨5.6%
  • 新浪财经.1小时前
  • 早盘:美股继续攀升 三大股指创盘中新高
  • 新浪美股.1小时前
  • 金融壹账通美国IPO:募资超3亿美元 平安集团加持
  • 新浪财经-自媒体综合.1小时前

更多

所属板块

制药
-0.05%
制药与医学研究
0.00%

热门股票

名称
价格
涨跌幅

EYEG 简况

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
展开

Webull提供Eyegate Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。